Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22315060 | 0.76 | SCN10A (0.47) | MRGPRX4SCN10AALDH1A1NPC1RAB9A | |
| SCHEMBL25865344 | 0.73 | EIF4E (0.44) | MRGPRX4SCN10ANPC1RAB9A | |
| SCHEMBL14729755 | 0.71 | MEN1 (0.46) | MRGPRX4SCN10APPARDALDH1A1NPC1 | |
| SCHEMBL22314946 | 0.70 | DGAT1 (0.50) | MRGPRX4SCN10AALDH1A1NPC1RAB9A | |
| SCHEMBL22314935 | 0.70 | PPARD (0.42) | MRGPRX4SCN10APPARDSCN2APPIA | |
| SCHEMBL13581056 | 0.70 | MRGPRX4 (0.55) | MRGPRX4PPARDPPIA | |
| SCHEMBL11670391 | 0.69 | CREBBP (0.57) | MRGPRX4PTGER1NPC1RAB9A | |
| SCHEMBL10742651 | 0.69 | MEN1 (0.60) | PPIAALDH1A1NPC1RAB9A | |
| SCHEMBL10739078 | 0.69 | ALDH1A1 (0.54) | ALDH1A1NPC1RAB9A | |
| SCHEMBL22145142 | 0.69 | ALDH1A1 (0.48) | TACR3PPIAPTGER1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | TACR3 557/4885MRGPRX4 2879/4885SCN10A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.